Two injections, two different jobs

The question is not which injection works better — it is which knee problem you have. Hyaluronic acid (HA) and ChondroFiller serve genuinely different purposes, and choosing between them starts with understanding what is actually wrong in the joint.

HA works by restoring lubrication. It supplements the synovial fluid that cushions and protects the knee, easing pain and stiffness caused by general joint wear. It does not repair cartilage.

ChondroFiller is an injectable collagen scaffold. Placed under ultrasound guidance into a focal, full-thickness cartilage defect, it creates a biological matrix that supports the body's own repair processes — recruiting the patient's progenitor cells to migrate in and begin regenerating tissue. It is not a general pain-relief injection.

Both are delivered as outpatient, ultrasound-guided injections at this clinic — neither requires surgery or a theatre admission. And they are not always an either/or choice: for some patients, they work best in sequence, addressing different aspects of the same knee.

How hyaluronic acid works — and what it can and cannot do

Synovial fluid naturally contains hyaluronic acid — a molecule that gives healthy joint fluid its thick, viscous consistency, allowing the knee to absorb load and move with minimal friction. In osteoarthritis, HA concentration and molecular weight both fall, leaving the joint relatively unprotected. Injected HA replaces that lost viscosity, restoring the fluid's shock-absorbing and lubricating properties without touching the cartilage structure itself.

In practice, patients typically notice some improvement within one to two weeks; the effect peaks at around six to eight weeks and generally lasts three to six months. Relief occasionally extends to twelve months, though that is not the usual expectation and should not be treated as the baseline. Once the body absorbs the injected HA — as it inevitably does — symptoms tend to return to their previous level, and repeat courses every six to twelve months become standard.

The evidence base is contested at guideline level. Multiple systematic reviews and Cochrane analyses, including Bellamy et al. (2006) and a network meta-analysis by Bannuru et al. (2015, Annals of Internal Medicine), support short-term efficacy in knee osteoarthritis. OARSI offers conditional support for viscosupplementation; AAOS and ACR are more cautious, citing only modest superiority over placebo in pooled analyses. Despite that disagreement, HA remains widely used in clinical practice, partly because access is straightforward and the safety profile is favourable — post-injection swelling affects roughly 5% of patients and is usually transient.

What HA cannot address is a focal, full-thickness cartilage defect — the kind where a discrete area of cartilage is gone entirely rather than thinned across the joint surface. In that situation, lubricating synovial fluid is not what is missing, and HA injection alone would not be the appropriate first step.

What ChondroFiller does — mechanism and current evidence

ChondroFiller is a CE-marked, acellular type I collagen hydrogel — a scaffold material, not a lubricant. Placed into a focal cartilage defect under ultrasound guidance, it gels within approximately three to five minutes, filling the void and creating a stable biological matrix. The active process that follows is called acellular matrix-induced chondrogenesis: the scaffold acts as a template that the body's own progenitor cells — drawn from surrounding synovium and subchondral bone — move into, proliferate within, and begin rebuilding around. No cell harvesting and no multiple procedural stages are involved.

The indication is specific. ChondroFiller is suited to focal, full-thickness (Grade IV) cartilage defects typically up to approximately 2.5–3 cm², in patients aged roughly 20–70 with contained lesions and without widespread osteoarthritis. Female sex and elevated BMI have been associated with poorer functional scores in some knee studies, which is why careful patient selection shapes outcomes.

The current peer-reviewed knee evidence is encouraging but still limited in volume. A 2024 clinical study by Simeonov (Journal of IMAB, n=17, mean age 31) reported meaningful improvement in both Lysholm and IKDC functional scores at twelve months following ChondroFiller treatment for focal chondral lesions — IKDC gains in the region of approximately 30 points. A 2025 prospective study by Demmer et al. (PMC12498443), comparing ChondroFiller-treated joints with untreated controls at follow-up arthroscopy, found significantly better cartilage quality in the treated group: median Outerbridge score 1.5 versus 3.0 (P=0.006) and ICRS grade 1 versus 3 (P=0.002).

Two honest caveats apply. Sample sizes across both studies remain small, and no head-to-head randomised controlled trial comparing ChondroFiller directly with HA in the knee has been published. Long-term knee-specific data beyond twelve months is still developing.

Which knee problem points to which injection

Imaging findings do most of the sorting work here. When an MRI shows diffuse cartilage thinning across multiple knee compartments — the classic pattern of age-related osteoarthritis — hyaluronic acid is the more appropriate injectable choice: the realistic goal is symptom management, and HA is well suited to it.

The picture changes when the scan identifies a discrete, contained, full-thickness loss — an Outerbridge or ICRS Grade III–IV lesion — in a patient with otherwise reasonable surrounding cartilage. That is the indication ChondroFiller is designed for. Accurate defect characterisation matters at this stage; AI-driven MRI analysis tools supporting cartilage segmentation and T2 mapping, such as onMRI™ used in the clinic's assessment pathway, can help define defect extent and depth before a treatment plan is made.

Age and activity level run through every part of this decision. ChondroFiller is suited to active patients aged approximately 20–70 who retain the biological capacity to recruit progenitor cells into the collagen scaffold. HA has no comparable age ceiling and remains a legitimate palliative option at any stage of knee osteoarthritis.

Published knee studies also identify biological sex and BMI as variables worth discussing: higher BMI and female sex have been linked to more variable functional outcomes following ChondroFiller in some series, though neither represents a fixed exclusion criterion. These factors are best weighed at a consultant assessment rather than used as a self-screening tool.

Where ChondroFiller is the intended approach but immediate symptom relief is pressing, HA can fulfil a palliative role in the interim — managing pain while imaging, planning, and treatment scheduling are completed.

Cost, access and the UK pathway

For most patients with knee osteoarthritis, hyaluronic acid is relatively straightforward to access. HA is available through NHS pathways in many parts of England, and covered by the majority of UK private health insurers — though NHS availability does vary by local prescribing policy, so it is worth confirming with your GP or insurer before assuming coverage.

ChondroFiller sits in a different funding category. It is not commissioned by the NHS and is not covered by major UK private medical insurers including BUPA and AXA. Patients access it on a self-funded private basis, with costs typically starting from around £3,000 depending on assessment requirements and the extent of the defect — a commitment worth establishing clearly before booking an appointment.

Whichever route is under consideration, a plain X-ray is not sufficient for the assessment. MRI with cartilage-specific reporting is the minimum standard to confirm whether a defect is focal and full-thickness or part of a more diffuse osteoarthritic picture — that distinction determines which treatment is appropriate.

No published cost-effectiveness trial has compared ChondroFiller and HA in the knee directly. Given that the two injections target different problems — symptom relief versus structural repair — a head-to-head cost comparison has limited practical value; the more useful question is which approach matches the injury and the patient's circumstances.

Lincolnshire Knee, part of the MSK Doctors group, accepts patients without a GP referral. Consultations and imaging are available at Sleaford (NG34) and Grantham (NG31).

Getting the right answer for your knee

The choice between these two injections ultimately reduces to one diagnostic question: is the cartilage problem focal or diffuse? A lubricant cannot repair a structural defect; a scaffold cannot manage generalised joint wear. Getting that question answered correctly — with MRI and a specialist clinical assessment — is the step that makes the injection decision meaningful rather than speculative.

An assessment at Lincolnshire Knee includes clinical evaluation of the knee alongside imaging review to confirm defect type, grade, location, and size before any pathway is recommended. Where the clinical picture warrants it, objective load and gait analysis through MAI Motion® can add further detail about the mechanical environment the cartilage is working in.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.